Pre-surgical targeted molecular therapy in renal cell carcinoma

Area of Science:

• Oncology
• Translational Research
• Surgical Oncology

Background:

• Pre-surgical systemic therapy with targeted molecular agents is being explored for renal cell carcinoma (RCC).
• This approach may help identify metastatic patients who will benefit from cytoreductive nephrectomy.
• It also allows for the study of molecular mechanisms of treatment response and resistance.

Purpose of the Study:

• To evaluate the potential of pre-surgical targeted therapy in managing renal cell carcinoma.
• To assess its role in patient selection for cytoreductive nephrectomy and in treating locally advanced disease.
• To explore its safety and utility in studying treatment response and resistance.

Main Methods:

• Review of preliminary evidence on pre-surgical targeted therapy in RCC.
• Analysis of the potential benefits for metastatic and locally advanced disease.
• Consideration of the need for prognostic biomarkers.

Main Results:

• Preliminary evidence suggests pre-surgical targeted therapies are safe in RCC patients.
• The strategy offers a rational approach for patient selection in metastatic RCC.
• It may improve resectability and facilitate timely systemic treatment for locally advanced RCC.

Conclusions:

• Pre-surgical targeted therapy is a promising strategy for RCC management.
• Further development of therapy-specific prognostic biomarkers is crucial for optimal integration with surgery.
• This approach aims to maximize oncological benefits for RCC patients.